Stephanie Okey, Director at Crinetics Pharmaceuticals, Inc. (CRNX), sold 3,000 shares at $39.67 ($119K) on 2026-03-03, disclosed to the SEC on 2026-03-04.
Scheduled sale ($119k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| PTCT | SELL | 2026-03-09 | $401K | — | Filing → |
| PTCT | SELL | 2025-03-17 | $270K | — | Filing → |
| CRNX | SELL | 2024-04-02 | $812K | — | Filing → |